ORIC reports preclinical data showing rinzimetostat boosts androgen‑receptor inhibitor sensitivity in prostate cancer
ORIC Pharmaceuticals presented preclinical and translational results at the ESMO Congress 2026 indicating that its PRC2‑EED inhibitor rinzimetostat enhances the response of prostate cancer cells to androgen‑receptor (AR) blockade. The data show maintained potency against EZH2‑inhibitor resistance mutations and synergistic activity with AR inhibitors in model systems and patient samples. ORIC’s chief scientific officer highlighted the findings as supporting a best‑in‑class profile and the ongoing Himalayas‑1 Phase 3 trial.
Why it matters
The company says the results strengthen the rationale for combining rinzimetostat with AR‑targeted therapies, which could improve the drug’s commercial potential if Phase 3 confirms efficacy. Investors may view the data as a positive catalyst for ORIC’s pipeline and future revenue prospects.
Key facts
- 1ORIC presented preclinical and translational data at ESMO Congress 2026 showing rinzimetostat enhances sensitivity to androgen‑receptor inhibition in prostate cancer. stocktitan.net
- 2Rinzimetostat maintained potency against a resistance‑conferring EZH2 mutation that reduced activity of the EZH2 inhibitor mevrometostat. stocktitan.net
- 3No hematologic tumorigenesis was observed in a rat toxicology study of rinzimetostat, unlike the EZH2 inhibitor tazemetostat. stocktitan.net
- 4ORIC’s chief scientific officer, Lori Friedman, PhD, said the data support a best‑in‑class profile and the ongoing Himalayas‑1 Phase 3 trial. stocktitan.net
- 5The company believes the data back the use of rinzimetostat across various prostate‑cancer disease settings. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.